Blog post Archive - ECCRT

|

  • No products in the cart.
  /  

Introduction Training is fundamental to clinical research, yet many organizations still debate whether to build programs internally or rely on external partners. As regulatory expectations rise and operational complexity increases, internal teams often struggle to maintain effective training at scale. This article explores the strengths and limitations of both approaches, and why many organizations are choosing to bring

Reaching Global Teams with Adaptive GCP Training at Scale Boehringer Ingelheim sought an innovative, scalable, and regulatorily aligned training solution to prepare its global workforce for the ICH-GCP E6 (R3) release. In collaboration with ECCRT, Boehringer Ingelheim co-developed a foundational eLearning course that not only met regulatory requirements but introduced adaptive design elements for greater learning efficiency.

  Building a GCP (Good Clinical Practice) training strategy in 2025 isn't just a compliance checkbox, it's a cornerstone of clinical research excellence. With regulations evolving and clinical trials becoming more complex, teams need smarter, scalable training that sticks. Understanding how to build a GCP training strategy in 2025 requires a comprehensive approach that goes beyond traditional

BIG partnered with ECCRT to refresh its team’s GCP knowledge, aligning with the latest ICH-GCP E6(R3) guidance. When some participants were unable to attend the live session, ECCRT seamlessly provided its GCP eLearning alternative—demonstrating flexibility and dedication to training access. About BIG The Breast International Group (BIG) is the largest global network entirely focused on academic breast cancer

The guide for clinical research or clinical project team development: how to build a high-performing team Recent research shows that the success rate of clinical trials is 10.8% across all therapeutic areas. Not very optimistic, right? It’s a well-known fact that clinical trials are complicated. Managing clinical trials is demanding and difficult to be efficient and effective

LIH needed to strengthen its understanding of medical device regulations and trial operations. ECCRT delivered tailored, practical classroom training that empowered the team to confidently manage device studies in full regulatory compliance. About the LIH The Luxembourg Institute of Health (LIH) is a public biomedical research organization focused on precision health and invested in becoming a leading reference

Inokura successfully equipped its team with the knowledge and confidence to navigate audits and inspections seamlessly. About Inokura Inokura is a pharmaceutical research organization dedicated to advancing clinical drug development. Committed to excellence and regulatory compliance, Inokura partners with leading experts to ensure high-quality standards across its clinical trials. The company operates with a strong focus on data

 Drug Development Smart Strategies: 1. Partnerability:Partnering is a core element for most Biotech business models. Partnering at the optimal point of their asset. Optimal Point is defined by proactively updating when new information arrives:Scientific read-outCompetitive LandscapeRecent dealsRegulatory decisionsetc

CTA negotiations can be a hurdle for trial initiation The amount of clinical trial agreements (CTAs) that a “contract manager” or a “project manager” (or any other name used within a company to identify a non-legally trained person in charge of the coordination of CTA negotiation and implementation) must handle for one single clinical study is generally

1. What is a Trial Master File (TMF)? Each clinical trial comes with documentation of trial related activities, legal requirements and trial data. All trial related documents need to be collected, organised, managed and maintained in what is called the “Trial Master File” or Electronic Trial Master File (eTMF). 2. Why is a TMF needed? A TMF is essential

User registration

Reset Password